Tuesday, January 28, 2025

Friends of Cancer Research: 2024 Year in Review (158pp)

Friends of Cancer Research has released its 2024 Year in Review, a 158-page PDF.  The event also celebreates the organization's 25th anniversary.

Find it here:

Home page:

https://friendsofcancerresearch.org/impact-reports/25th-anniversary-impact-report/

PDF:

https://friendsofcancerresearch.org/wp-content/uploads/Friends-Scientific-Report_2024.pdf



The 158-page report includes full reprints of a number the organization's sponsored publications, such as Andrews et al, analysis of 20 assays to mreasure homologous recombination deficiency (Andrews et al, JCO Oncol Adv).  There are also white papers, such as a framework for integrating ctDNA changes into cancer clinical trials (p. 110ff).  There is also a white paper for pragmatic post-market trials (p. 59ff) which is paired with an op-ed on RWE (Stewart et al., ESMO J.)




####

AI Corner

AI Summary (Chat GPT4)

Highlight Summary for Blog Readers:

The Friends of Cancer Research 2024 Scientific Report showcases significant strides in oncology drug development and policy. Key themes include enhancing diversity in clinical trials, leveraging real-world evidence for regulatory decisions, advancing early endpoints and cell/gene therapy frameworks, and harmonizing biomarker diagnostics with AI applications. 

Notable initiatives include the Homologous Recombination Deficiency (HRD) project and the Digital PATH project, targeting variability in diagnostic tests and AI model outputs. 

This work underscores the importance of collaboration and innovation in improving cancer care and regulatory pathways. Full report details these advancements, emphasizing patient-centric approaches.

##